BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang M, Yuan L, Qiao B, Li Y. Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine. Virus Genes 2014;48:32-7. [PMID: 24203098 DOI: 10.1007/s11262-013-1004-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang HL, Lu X, Yang X, Xu N. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract 2016;2016:3435965. [PMID: 27672391 DOI: 10.1155/2016/3435965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
2 Wang HL, Lu X, Yang X, Ning Q. Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015; Nov 24. [Epub ahead of print]. [PMID: 26621535 DOI: 10.1016/j.clinre.2015.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
3 Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med. 2016;11:2293-2299. [PMID: 27313669 DOI: 10.3892/etm.2016.3230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Zhang C, Ke W, Liu L, Gao Y, Yao Z, Ye X, Zhou S, Yang Y. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. Drug Des Devel Ther 2016;10:897-910. [PMID: 27041994 DOI: 10.2147/DDDT.S98200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]